Ozagrel (sodium)

Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases^{[1][2][3][4][5]}. IC50 & Target:Thromboxane A2 Synthase In Vitro:Ozagrel sodium significantly inhibits platelet aggregation induced by Arachidonic acid (HY-109590) with an IC₅₀ of 53.12 μM^[1].
Ozagrel sodium (100 μM) exhibits the inhibitory rate on plasma TXB₂ of 99.6% but has no inhibitory effect on PGH₂^[1].
In Vivo:Ozagrel sodium (10-20 mg/kg, p.o., once daily for 6-21 days) markedly improves extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced by L-Methionine (HY-N0326) and bilateral common carotid artery occlusion (BCCAo)^[2][3].
Ozagrel (80 mg/kg, i.v., single dose) sodium attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in Oleic acid (OA) (HY-N1446)-induced lung injury in guinea pigs^[4].